What is the recommended indication, dosing regimen, contraindications, and monitoring for tranexamic acid in children with severe multitrauma at risk of significant hemorrhage?

Tranexamic Acid for Pediatric Multitrauma

Tranexamic acid should be administered to children with severe multitrauma at risk of significant hemorrhage using a loading dose of 15 mg/kg (maximum 1 g) over 10 minutes, followed by a maintenance infusion of 2 mg/kg/hr for 8 hours, initiated as early as possible and within 3 hours of injury. 1

Indications

• Pediatric trauma patients with active bleeding or at risk of significant hemorrhage should receive TXA as part of massive hemorrhage protocols. 1
• The drug is most beneficial in children with hemodynamic instability, ongoing hemorrhage, or massive transfusion requirements (≥40 mL/kg blood products within 24 hours). 2
• TXA reduces mortality in pediatric combat trauma requiring massive transfusions, with an odds ratio of 0.35 for death (95% CI 0.123-0.995). 2

Dosing Regimen

Loading Dose

• Administer 15 mg/kg IV over 10 minutes (maximum 1 g in children >12 years who should receive adult dosing). 1
• Recent pharmacokinetic modeling suggests 25 mg/kg (maximum 2 g) may better approximate adult exposure levels, though this remains investigational. 3
• The 15 mg/kg dose is the established guideline recommendation and most commonly used in U.S. pediatric trauma centers (68% of centers using TXA). 1, 4

Maintenance Infusion

• Follow with 2 mg/kg/hr continuous infusion for 8 hours. 1
• This maintenance regimen is used by 87% of pediatric trauma centers administering TXA, with 54% specifically using the 2 mg/kg/hr × 8 hours protocol. 4

Weight-Based Modifications

• Prescribe TXA in volume (mL) rather than units, with sensible rounding for practical administration. 1
• Children >12 years should receive standard adult dosing (1 g loading dose, 1 g over 8 hours). 1

Critical Timing Considerations

The treatment window is absolutely critical and non-negotiable:

• Initiate TXA immediately upon recognition of significant hemorrhage, ideally within 1 hour of injury. 5, 6
• Treatment within 2 hours provides the greatest relative risk reduction in mortality. 6
• Administration between 1-3 hours still provides benefit but with 10% decreased efficacy for every 15-minute delay. 7, 5
• Do NOT administer TXA after 3 hours from injury—this may paradoxically increase bleeding death risk (RR 1.44). 7, 5, 6
• In children with severe traumatic brain injury (GCS <9), treatment benefits may extend beyond 2 hours, but the 3-hour absolute cutoff still applies. 6

Contraindications

Absolute Contraindications

• Active intravascular clotting or disseminated intravascular coagulation 8
• Severe hypersensitivity to tranexamic acid 8
• Subarachnoid hemorrhage (risk of cerebral edema and infarction) 7

Relative Contraindications Requiring Caution

• Massive hematuria (risk of ureteric obstruction from clot formation) 8, 9
• Known thrombophilia or recent thromboembolic event 8
• Severe renal impairment (requires dose adjustment—see below) 1

Monitoring Requirements

Essential Pre-Administration Assessment

• Assess time from injury—this is the single most critical factor determining benefit versus harm. 5, 6
• Evaluate for active bleeding, hemodynamic instability (hypotension, tachycardia), and estimated blood loss. 1
• Check renal function (creatinine clearance) before administration, as TXA is 90% renally excreted and accumulates in renal dysfunction. 9

Renal Dose Adjustments

• For creatinine clearance 30-50 mL/min: Extend dosing interval to every 8-12 hours. 9
• For creatinine clearance <30 mL/min: Extend dosing interval to every 12-24 hours. 9
• Failure to adjust dosing in renal impairment significantly increases seizure risk and neurotoxicity. 9

Ongoing Monitoring

• Monitor for signs of ongoing hemorrhage and response to resuscitation. 1
• No routine coagulation monitoring is required for TXA itself, as it does not alter standard coagulation tests. 9
• If available, thromboelastography (TEG/ROTEM) can identify candidates who would most benefit from antifibrinolytic therapy. 4
• Monitor for electrolyte imbalances and hypothermia during rapid blood product administration—children are at particular risk. 1

Laboratory Tests NOT Required

• Viscoelastic testing is NOT required before administering TXA in acute trauma. 9
• Do not delay TXA administration waiting for laboratory results. 8

Integration with Massive Hemorrhage Protocols

TXA is an adjunct to—not a substitute for—definitive hemorrhage control:

• Ensure clinical treatment is constantly directed toward hemorrhage control using temporary hemostatic devices (pressure, tourniquets) followed by surgical or interventional radiological control. 1
• Activate massive transfusion protocol for children with hemorrhagic shock, active bleeding, and systolic blood pressure <90 mmHg. 8
• Deliver blood products empirically at first: FFP 10-15 mL/kg, platelets 10-20 mL/kg, cryoprecipitate 5-10 mL/kg. 1
• Maintain permissive hypotension (systolic 80-100 mmHg) until hemorrhage control, except in traumatic brain injury or spinal cord injury. 1, 8
• Avoid crystalloid and colloid administration during uncontrolled hemorrhage—use only for profound hypotension when blood products are unavailable. 1, 8

Common Pitfalls to Avoid

• Do not delay TXA administration beyond 3 hours from injury—this is harmful, not neutral. 7, 5, 6
• Do not use TXA as a substitute for surgical hemorrhage control—it is an adjunct only. 1
• Do not administer TXA intrathecally—this causes severe neurotoxicity and is absolutely contraindicated. 8
• Do not withhold TXA due to thrombotic concerns in appropriate bleeding scenarios—no increased thromboembolic risk has been demonstrated in pediatric or adult trauma populations. 1, 8, 2
• Do not forget to assess renal function and adjust dosing accordingly—this is the most critical safety error. 9
• Do not use topical TXA as a substitute for IV administration in multitrauma—systemic fibrinolysis requires systemic therapy. 8

Safety Profile

• TXA has been successfully used in elective pediatric surgery with significant reduction in blood loss and transfusion requirements. 4
• No increased risk of thromboembolic events has been demonstrated in pediatric trauma populations. 1, 2
• The most common adverse effect is seizures, particularly with higher doses (>100 mg/kg total dose) or in patients with renal impairment. 7, 9
• Children are at particular risk of hypothermia and electrolyte imbalances during rapid blood product administration, requiring vigilant monitoring. 1